Phellinus Igniarius Study: Immune Recovery After Chemo
A 2026 clinical trial suggests Phellinus igniarius decoction may help restore immune function in colorectal cancer patients following chemotherapy. Read the findings.
For colorectal cancer patients navigating life after chemotherapy, immune dysfunction is one of the most persistent and clinically serious challenges they face. Now, a prospective randomized controlled trial published in the Journal of Traditional and Complementary Medicine (Zhang H, Li W, Hu D, et al., 2026) suggests that a traditional Chinese medicinal fungus — Phellinus igniarius — may offer meaningful support for immune recovery in this vulnerable population. The findings add a new dimension to the growing conversation around integrative oncology and evidence-based complementary medicine.
What This Study Found
The clinical trial enrolled colorectal cancer (CRC) patients who had completed chemotherapy between January 2021 and June 2024. Participants were randomized in a 1:4:1 ratio to receive either a placebo (n=33), Phellinus igniarius Decoction (PEG) at 15 g/day orally (n=132), or thymalfasin — a well-established immunomodulatory agent administered subcutaneously at 1.6 mg twice weekly (n=33). All interventions were administered for eight weeks.
Researchers measured primary outcomes including changes in peripheral blood immune cell subsets — specifically the CD4+/CD8+ T cell ratio and the percentage of natural killer (NK) cells — as well as cytokine profiles reflecting the Th1/Th2 immune balance. Secondary outcomes included quality of life (QOL) scores assessed using the validated EORTC QLQ-C30 instrument, along with adverse event monitoring.
The results were notable. The study found that patients in the PEG group demonstrated significant increases in the proportion of CD4+ T cells (p < 0.001) and NK cell percentages (p < 0.05) compared to baseline. Levels of Th1-associated cytokines — including interleukin-2 (IL-2) and interferon-gamma (IFN-γ) — were significantly elevated, while Th2 and pro-inflammatory markers such as IL-4, IL-10, and TNF-α were meaningfully reduced (p < 0.05). Quality of life scores also improved significantly in the PEG group (p < 0.05), and adverse event rates were described as comparable to those observed in control groups.
A particularly interesting finding emerged from subgroup analysis: patients classified under the Traditional Chinese Medicine (TCM) syndrome type known as spleen-kidney deficiency syndrome appeared to be the optimal responder subgroup, suggesting that individualized TCM diagnosis may help identify which patients are most likely to benefit from PEG therapy.
Clinical Significance
Chemotherapy-induced immune dysfunction is a well-recognized complication of CRC treatment. The suppression of T cell populations and disruption of cytokine balance can impair the body's ability to surveil and respond to residual or recurrent malignant cells, potentially worsening long-term prognosis. Despite this, pharmacological options for restoring post-chemotherapy immune function remain limited and are not universally accessible.
Phellinus igniarius, sometimes called the fire sponge fungus or willow bracket, has a long history of use in East Asian traditional medicine. It contains bioactive polysaccharides and phenolic compounds that have previously been associated with immunomodulatory activity in preclinical settings. However, rigorous clinical evidence has historically been scarce — a gap this prospective, randomized, controlled trial directly addresses.
The study suggests that oral administration of PEG may favorably shift the immune environment in post-chemotherapy CRC patients by promoting Th1 dominance — a cytokine profile generally associated with more robust anti-tumor immunity — while dampening excessive Th2 and inflammatory signaling. Researchers also found that improvements in measurable immune parameters were accompanied by enhanced patient-reported quality of life, which is a critical endpoint in oncology care that is sometimes overlooked in purely biological outcome studies.
It is important to contextualize these findings appropriately. While the randomized controlled design strengthens confidence in the results, the study was conducted within a specific patient population using TCM syndrome classification, and further replication in diverse clinical settings will be necessary before broad clinical recommendations can be made. The study suggests promising outcomes, but it does not establish PEG as a standard-of-care intervention at this stage.
Current Access and Compliance Context
Phellinus igniarius preparations are not yet widely integrated into Western oncology protocols, and the specific decoction formulation (PEG) used in this trial — administered at 15 g/day orally — may not be readily available through conventional pharmacy channels in many countries. In jurisdictions where TCM practitioners are licensed, patients may be able to access Phellinus igniarius-based preparations, though product standardization can vary significantly between suppliers and formulations.
The eight-week treatment duration used in this study also underscores the importance of consistent compliance. As with many botanical and complementary interventions, the immune benefits observed appeared to accumulate over the course of the treatment period, suggesting that short-term or irregular use may not replicate the outcomes described by researchers.
Practitioners considering integrative applications of this research should also be mindful of the TCM subgroup finding. The study suggests that patients identified as having spleen-kidney deficiency syndrome — a classification requiring assessment by a qualified TCM practitioner — may represent the primary beneficiary population. This highlights the potential value of interdisciplinary collaboration between oncologists and licensed TCM clinicians.
What Patients Should Know
If you are a colorectal cancer patient who has completed chemotherapy and are experiencing ongoing fatigue, reduced immune resilience, or a diminished sense of well-being, this research may be worth discussing with your healthcare provider. The study suggests that Phellinus igniarius decoction was well tolerated, with adverse event rates comparable to placebo and thymalfasin groups — an encouraging safety signal, though individual responses can vary.
Patients should not self-prescribe or self-administer any herbal decoction without medical supervision, particularly during or after cancer treatment. Interactions with ongoing medications, the precise formulation and dosage, and the clinical appropriateness of this intervention for your specific situation all require evaluation by a qualified healthcare professional familiar with both your oncological history and complementary medicine approaches.
It is also worth noting that this study evaluated a specific standardized decoction preparation. Over-the-counter supplements marketed under similar names may differ substantially in their composition, potency, and quality. Always seek guidance from a licensed and experienced practitioner before initiating any complementary therapy.
Conclusion
The 2026 prospective clinical trial by Zhang et al. represents a meaningful contribution to the evidence base for integrative oncology. The study suggests that Phellinus igniarius Decoction (PEG) may help restore measurable immune function and improve quality of life in colorectal cancer patients following chemotherapy, with a particularly strong response observed in those presenting with spleen-kidney deficiency syndrome according to TCM classification. While further research and replication are needed, these findings offer a compelling rationale for continued investigation and open an important dialogue between conventional oncology and evidence-informed complementary medicine.
If you are interested in exploring integrative approaches to post-chemotherapy recovery with a qualified and knowledgeable practitioner, we encourage you to visit peptideassociation.org/find-a-doctor to connect with a healthcare professional in your area who can guide you based on your individual clinical needs.
Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The content presented here is based on a single published research study and should not be used as the sole basis for any clinical or personal health decision. Always consult a qualified and licensed healthcare provider before beginning, modifying, or discontinuing any medical treatment or complementary therapy, particularly in the context of cancer care.
Citation (AMA Format): Zhang H, Li W, Hu D, et al. A prospective clinical study on the effectiveness of Phellinus igniarius decoction in treating immune dysfunction in colorectal cancer patients following chemotherapy. J Tradit Complement Med. 2026. doi:10.1016/j.jtcme.2026.05.002. PMID: 42698582.
Ready to work with a peptide-specialized clinician?
The Peptide Association works with licensed clinicians across the United States who specialize in peptide therapy, with telehealth options available in most states.
Disclosure: Peptide Association LLC has a financial relationship with this provider and receives compensation when you book or become a patient. This is a paid referral. See exactly how we make money.